Inovio Pharmaceuticals, Inc. (INO) CEO Jacque Shea Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 12:40 PM ET

Company Participants

Jacque Shea - President and CEO

Conference Call Participants

Hartaj Singh - Oppenheimer

Hartaj Singh

Great, thank you operator for again, always making this so seamless and easy for us all. We have now Jacque Shea, the President and CEO of Inovio Company we've been covering for a while now. And we recently upgraded on the back of some really compelling data, they've presented RFP and conversations they've had with regulators. It's a company that could have their first approved product, sometime hopefully next year.

And Jacque will give us a quick update for about three to five minutes on the state affairs on Inovio. And then after that, we'll jump into our fireside chat. So with that, please, Jacque, take it away.

Jacque Shea

Hey, and thank you very much, Hartaj, for having us delighted to be here today to tell you a bit about Inovio. And the really fantastic progress we've made over the past 12 months or so.

So I'll start off by saying, over the over the past 12 months, we've really made some great progress on 3107. But that has also come off the back of some work that we've really been doing to reshape and Inovio. So I became CEO in May 2022. And since then, what I've really been looking at is prioritizing our late-stage pipeline, and making sure that we're really focusing our efforts on those late-stage programs that have meets high unmet medical needs, have good commercial potential, and have appropriate pathways to market.

So focusing on those late-stage candidates. I've also been looking at the structure of the organization, looking at our cash burn, and over the past year or so we've reduced down